Clinical Laserthermia Systems AB

Clinical Laserthermia Systems AB operates with a current liquidity position that is medium risk, as indicated by a negative net cash position after accounting for total debt. The company's liquidity FPT (free cash flow to total liabilities) is weak, with a free cash flow of -11,974,000 SEK and total liabilities of 8,477,000 SEK. The current ratio of 2.55 suggests the company can cover its short-term obligations, but the negative operating cash flow of -20,527,000 SEK indicates ongoing cash outflows from operations.

Profitability metrics are deeply negative, with a return on equity of -24.46% and a return on assets of -20.95%. These figures are well below the industry median for Advanced Medical Equipment & Technology, which typically sees positive returns in the 5-10% range. The company's operating income of -16,992,000 SEK and net income of -12,397,000 SEK further underscore the lack of profitability.

The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to market-specific risks, particularly in the healthcare equipment sector where regulatory and reimbursement changes can significantly impact revenue. No material geographic breakdown is available in the latest financials, but the company is headquartered in Sweden, suggesting a potential regional focus.

Growth expectations are mixed. Analysts estimate a revenue increase to 38,000,000 SEK in the next fiscal year, up from 31,400,000 SEK in the current year. However, EBIT is expected to remain negative at -25,000,000 SEK, indicating continued operational losses. The company's capital expenditures are minimal at -6,000 SEK, suggesting limited investment in growth infrastructure.

The risk profile is elevated due to the company's negative cash flows and lack of profitability. The liquidity risk is medium, with a debt-to-equity ratio of 0.01 and a current ratio of 2.55. The dilution risk is low, with no significant changes in shares outstanding between basic and diluted shares. However, the negative operating cash flow and high net losses suggest a potential need for future financing, which could lead to dilution.

Recent events include a consistent pattern of negative cash flows and operating losses. The company's latest financial filing shows a continuation of this trend, with no material changes in business operations or strategic direction disclosed in the latest 10-K or earnings call transcripts.

Revenue grew at a 67.1% CAGR over four years, demonstrating strong top-line expansion momentum for the company.

Operating income improved by 46.9% year-over-year in FY2026, signaling significant progress toward operational profitability.

Free cash flow improved by 18.8% year-over-year, indicating better cash generation efficiency despite ongoing losses.

The company holds zero long-term debt in FY2026, eliminating interest expenses and reducing financial leverage risks.

Cash conversion ratio of 1.66 ranks in the top quartile of the advanced medical equipment cohort.

The company reported a net loss of 41.6 million SEK in FY2026, continuing its history of unprofitability.

Operating margin of -5.41% places the company in the bottom quartile of its peer cohort.

The company faces medium liquidity risk, which could constrain operations given its negative cash flow position.

Revenue kr 830.0k, −82,0% YoY; Operating income +27,8% YoY.

• ▍Revenue kr 830.0k, −82,0% YoY
• ▍Operating income +27,8% YoY
• ▍Net income −37,3% YoY
• ▍Free cash flow −20,9% YoY
• ▍Net margin -1434.0%

Revenue kr 2.8M, −48,2% YoY; Operating income +23,4% YoY.

• ▍Revenue kr 2.8M, −48,2% YoY
• ▍Operating income +23,4% YoY
• ▍Net income +37,2% YoY
• ▍Free cash flow +44,2% YoY
• ▍Net margin -290.7%

Revenue kr 9.4M, +66,5% YoY; Operating income +77,4% YoY.

• ▍Revenue kr 9.4M, +66,5% YoY
• ▍Operating income +77,4% YoY
• ▍Net income +53,3% YoY
• ▍Free cash flow +56,6% YoY
• ▍Net margin -67.8%

Revenue kr 4.5M, +43,2% YoY; Operating income +53,7% YoY.

• ▍Revenue kr 4.5M, +43,2% YoY
• ▍Operating income +53,7% YoY
• ▍Net income −22,8% YoY
• ▍Free cash flow −26,3% YoY
• ▍Net margin -338.6%

Revenue kr 4.6M; Operating income -kr 14.7M.

• ▍Revenue kr 4.6M
• ▍Operating income -kr 14.7M
• ▍Net margin -188.0%

Revenue kr 5.4M; Operating income -kr 9.7M.

• ▍Revenue kr 5.4M
• ▍Operating income -kr 9.7M
• ▍Net margin -239.7%

Revenue kr 5.6M; Operating income -kr 12.9M.

• ▍Revenue kr 5.6M
• ▍Operating income -kr 12.9M
• ▍Net margin -241.7%

Revenue kr 3.1M; Operating income -kr 17.0M.

• ▍Revenue kr 3.1M
• ▍Operating income -kr 17.0M
• ▍Net margin -394.8%

Revenue kr 17.5M, −6,9% YoY; Operating income +46,9% YoY.

• ▍Revenue kr 17.5M, −6,9% YoY
• ▍Operating income +46,9% YoY
• ▍Net income +12,6% YoY
• ▍Free cash flow +18,8% YoY
• ▍Net margin -238.0%

Revenue kr 18.8M, +127,0% YoY; Operating income +17,7% YoY.

• ▍Revenue kr 18.8M, +127,0% YoY
• ▍Operating income +17,7% YoY
• ▍Net income +40,3% YoY
• ▍Free cash flow +38,0% YoY
• ▍Net margin -253.5%

Revenue kr 8.3M, +32,0% YoY; Operating income +2,2% YoY.

• ▍Revenue kr 8.3M, +32,0% YoY
• ▍Operating income +2,2% YoY
• ▍Net income −12,9% YoY
• ▍Free cash flow −21,1% YoY
• ▍Net margin -964.5%

Revenue kr 6.3M, +179,2% YoY; Operating income −11,1% YoY.

• ▍Revenue kr 6.3M, +179,2% YoY
• ▍Operating income −11,1% YoY
• ▍Net income −11,1% YoY
• ▍Free cash flow −12,0% YoY
• ▍Net margin -1127.3%